





Recently, Acting FDA Commissioner Andrew C. von Eschenbach offered testimony before a House subcommittee. During Q&A, he was pressed on the matter of the continually pending RX to OTC switch of Plan B oral contraceptive, popularly known as the "morning … Continue reading